Banque Pictet & Cie SA Cuts Position in TG Therapeutics, Inc. $TGTX

Banque Pictet & Cie SA decreased its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 6.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,324 shares of the biopharmaceutical company’s stock after selling 827 shares during the quarter. Banque Pictet & Cie SA’s holdings in TG Therapeutics were worth $444,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TGTX. GAMMA Investing LLC raised its position in TG Therapeutics by 6,905.5% in the first quarter. GAMMA Investing LLC now owns 179,130 shares of the biopharmaceutical company’s stock valued at $7,063,000 after purchasing an additional 176,573 shares during the period. NBC Securities Inc. increased its position in shares of TG Therapeutics by 82,300.0% during the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 823 shares during the period. First Citizens Bank & Trust Co. purchased a new stake in shares of TG Therapeutics during the first quarter worth $211,000. Daymark Wealth Partners LLC increased its position in shares of TG Therapeutics by 9.6% during the first quarter. Daymark Wealth Partners LLC now owns 45,500 shares of the biopharmaceutical company’s stock worth $1,794,000 after acquiring an additional 4,000 shares during the period. Finally, USA Financial Formulas purchased a new stake in shares of TG Therapeutics during the first quarter worth $57,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $35.50 on Friday. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. The firm has a fifty day moving average price of $31.58 and a 200 day moving average price of $35.57. The company has a market cap of $5.63 billion, a P/E ratio of 95.95 and a beta of 1.88. TG Therapeutics, Inc. has a 12 month low of $21.16 and a 12 month high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.15). The firm had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business’s revenue for the quarter was up 92.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.04 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Activity at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of the business’s stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the transaction, the director owned 94,061 shares in the company, valued at approximately $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 10.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on TGTX. B. Riley upped their price objective on TG Therapeutics from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. The Goldman Sachs Group raised TG Therapeutics to a “hold” rating and set a $37.00 price objective on the stock in a research report on Thursday, July 10th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $48.00.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.